Tom 14, Nr 4 (2017)
Niewydolność serca
Opublikowany online: 2017-12-06
Wyświetlenia strony
698
Wyświetlenia/pobrania artykułu
2220
Aktualne spojrzenie na parametry czerwonokrwinkowe w niewydolności serca
Choroby Serca i Naczyń 2017;14(4):201-206.
Streszczenie
Niewydolność serca (HF) jest narastającym problemem i dotyczy obecnie 1–2% populacji, a jej objawy stanowią główną przyczynę hospitalizacji u osób powyżej 65. roku życia. W ocenie skuteczności leczenia HF są stosowane parametry kliniczne (np. duszność, obrzęki, zmiana masy ciała) oraz laboratoryjne (np. peptydy natriuretyczne), wśród których coraz więcej uwagi poświęca się parametrom czerwonokrwinkowym. Wartości hemoglobiny i hematokrytu to przede wszystkich podstawa rozpoznanie niedokrwistości, która często towarzyszy HF i pogarsza rokowanie w tej chorobie. Okazuje się jednak, że parametry te mogą być również przydatne w monitorowaniu zmian wolemii związanej ze stosowaniem diuretyków, umożliwiając identyfikację chorych opornych na leczenie moczopędne. Ocena zjawiska hemokoncentracji może być przydatna w optymalizacji dawkowania diuretyków oraz interpretacji często obserwowanych w przebiegu leczenia zaostrzeń HF wahań stężenia parametrów nerkowych. Celem prezentowanej pracy jest przedstawienia aktualnego stanu wiedzy na temat możliwości wykorzystania parametrów czerwonokrwinkowych w ocenie chorych na HF.
Słowa kluczowe: niewydolność sercaniedokrwistośćhemoglobinahematokrytprzewodnienieniedobór żelazadiuretyki
Referencje
- Karasek D, Kubica A, Sinkiewicz W, et al. Epidemia niewydolności serca — problem zdrowotny i społeczny starzejących się społeczeństw Polski i Europy. Folia Cardiol Excerpta. 2008; 3(5): 242–248.
- Gierczynski J, Gryglewicz J, Karczewicz E. Niewydolność serca — analiza kosztów ekonomicznych i społecznych. Instytut Zarządzania w Ochronie Zdrowia Uczelni Łazarskiego, Warszawa 2013: 1–54.
- Ponikowski P, Voors A, Anker S, et al. Wytyczne ESC dotyczące diagnostyki i leczenia ostrej i przewlekłej niewydolności serca w 2016 roku. Kardiol Pol. 2016; 74(10): 1037–1147.
- Adams KF, Fonarow GC, Emerman CL, et al. ADHERE Scientific Advisory Committee and Investigators. Characteristics and outcomes of patients hospitalized for heart failure in the United States: rationale, design, and preliminary observations from the first 100,000 cases in the Acute Decompensated Heart Failure National Registry (ADHERE). Am Heart J. 2005; 149(2): 209–216.
- O'Connor CM, Stough W, Gallup D, et al. Demographics, clinical characteristics, and outcomes of patients hospitalized for decompensated heart failure: observations from the IMPACT-HF Registry. J Cardiac Failure. 2005; 11(3): 200–205.
- Fonarow GC, Stough WG, Abraham WT, et al. OPTIMIZE-HF Investigators and Hospitals. Characteristics, treatments, and outcomes of patients with preserved systolic function hospitalized for heart failure: a report from the OPTIMIZE-HF Registry. J Am Coll Cardiol. 2007; 50(8): 768–777.
- Ranasinghe I, Wang Y, Dharmarajan K, et al. Diagnoses and timing of 30-day readmissions after hospitalization for heart failure, acute myocardial infarction, or pneumonia. JAMA. 2013; 309(4): 355–363.
- Passantino A, Guida P, Lagioia R, et al. Predictors of long-term mortality in older patients hospitalized for acutely decompensated heart failure: clinical relevance of natriuretic peptides. J Am Geriatr Soc. 2017; 65(4): 822–826.
- Porapakkham P, Porapakkham P, Zimmet H, et al. B-type natriuretic peptide-guided heart failure therapy: a meta-analysis. Arch Intern Med. 2010; 170(6): 507–514.
- Berger R, Moertl D, Peter S, et al. N-terminal pro-B-type natriuretic peptide-guided, intensive patient management in addition to multidisciplinary care in chronic heart failure a 3-arm, prospective, randomized pilot study. J Am Coll Cardiol. 2010; 55(7): 645–653.
- Januzzi JL, Rehman SU, Mohammed AA, et al. Use of amino-terminal pro-B-type natriuretic peptide to guide outpatient therapy of patients with chronic left ventricular systolic dysfunction. J Am Coll Cardiol. 2011; 58(18): 1881–1889.
- Singer AJ, Birkhahn RH, Guss D, et al. Rapid Emergency Department Heart Failure Outpatients Trial (REDHOT II): a randomized controlled trial of the effect of serial B-type natriuretic peptide testing on patient management. Circ Heart Fail. 2009; 2(4): 287–293.
- Kociol RD, McNulty SE, Hernandez AF, et al. Markers of decongestion, dyspnea relief, and clinical outcomes among patients hospitalized with acute heart failure. Circ Heart Fail. 2012; 6(2): 240–245.
- Mehta RH, Rogers JG, Hasselblad V, et al. Evaluation Study of Congestive Heart Failure and Pulmonary Artery Catheterization Effectiveness (ESCAPE) Trial Investigators. Association of weight change with subsequent outcomes in patients hospitalized with acute decompensated heart failure. Am J Cardiol. 2009; 103(1): 76–81.
- Jankowska EA, Kasztura M, Sokolski M, et al. Iron deficiency defined as depleted iron stores accompanied by unmet cellular iron requirements identifies patients at the highest risk of death after an episode of acute heart failure. Eur Heart J. 2014; 35(36): 2468–2476.
- Tang YD, Katz SD. The prevalence of anemia in chronic heart failure and its impact on the clinical outcomes. Heart Fail Rev. 2008; 13(4): 387–392.
- Klip IT, Comin-Colet J, Voors AA, et al. Iron deficiency in chronic heart failure: an international pooled analysis. Am Heart J. 2013; 165(4): 575–582.e3.
- Jankowska EA, von Haehling S, Anker SD, et al. Iron deficiency and heart failure: diagnostic dilemmas and therapeutic perspectives. Eur Heart J. 2013; 34(11): 816–829.
- O'Meara E, Rouleau JL, White M, et al. ANCHOR Investigators. Heart failure with anemia: novel findings on the roles of renal disease, interleukins, and specific left ventricular remodeling processes. Circ Heart Fail. 2014; 7(5): 773–781.
- Palazzuoli A, Gallotta M, Iovine F, et al. Niedokrwistość w niewydolności serca: częste współwystępowanie z niewydolnością nerek, czyli zespół niedokrwistości sercowo-nerkowej. Folia Cardiol Excerpta. 2008; 3(5): 264–270.
- Grote Beverborg N, van Veldhuisen DJ, van der Meer P. Anemia in heart failure: still relevant? JACC Heart Fail. 2017 [Epub ahead of print].
- Celik T, Iyisoy A, Kursaklioglu H, et al. Anemia and cardio-renal syndrome: a deadly association? Int J Cardiol. 2008; 128(2): 255–256.
- Silverberg DS, Wexler D, Iaina A. The importance of anemia and its correction in the management of severe congestive heart failure. Eur J Heart Fail. 2002; 4(6): 681–686.
- Jankowska EA, Rozentryt P, Witkowska A, et al. Iron deficiency: an ominous sign in patients with systolic chronic heart failure. Eur Heart J. 2010; 31(15): 1872–1880.
- Jankowska EA, Malyszko J, Ardehali H, et al. Iron status in patients with chronic heart failure. Eur Heart J. 2013; 34(11): 827–834.
- Anker SD, Comin Colet J, Filippatos G, et al. FAIR-HF Trial Investigators. Ferric carboxymaltose in patients with heart failure and iron deficiency. N Engl J Med. 2009; 361(25): 2436–2448.
- Raja RM, Po CL. Plasma refilling during hemodialysis with decreasing ultrafiltration. Influence of dialysate sodium. ASAIO J. 1994; 40(3): M423–M425.
- Boyle A, Sobotka PA. Redefining the therapeutic objective in decompensated heart failure: hemoconcentration as a surrogate for plasma refill rate. J Card Fail. 2006; 12(4): 247–249.
- Yancy CW, Jessup M, Bozkurt B, et al. 2017 ACC/AHA/HFSA Focused Update of the 2013 ACCF/AHA Guideline for the Management of Heart Failure: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Failure Society of America. J Card Fail. 2017; 23(8): 628–651.
- Yancy CW, Jessup M, Bozkurt B, et al. American College of Cardiology Foundation, American Heart Association Task Force on Practice Guidelines. 2013 ACCF/AHA guideline for the management of heart failure: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol. 2013; 62(16): e147–e239.
- Vaduganathan M, Greene SJ, Fonarow GC, et al. Hemoconcentration-guided diuresis in heart failure. Am J Med. 2014; 127(12): 1154–1159.
- Testani JM, Chen J, McCauley BD, et al. Potential effects of aggressive decongestion during the treatment of decompensated heart failure on renal function and survival. Circulation. 2010; 122(3): 265–272.
- Ter Maaten JM, Valente MAE, Damman K, et al. Combining Diuretic Response and Hemoconcentration to Predict Rehospitalization After Admission for Acute Heart Failure. Circ Heart Fail. 2016; 9(6).
- Oh J, Kang SM, Hong N, et al. Hemoconcentration is a good prognostic predictor for clinical outcomes in acute heart failure: data from the Korean Heart Failure (KorHF) Registry. Int J Cardiol. 2013; 168(5): 4739–4743.
- Davila C, Reyentovich A, Katz SD. Clinical correlates of hemoconcentration during hospitalization for acute decompensated heart failure. J Card Fail. 2011; 17(12): 1018–1022.
- Breidthardt T, Weidmann ZM, Twerenbold R, et al. Impact of haemoconcentration during acute heart failure therapy on mortality and its relationship with worsening renal function. Eur J Heart Fail. 2017; 19(2): 226–236.
- van der Meer P, Postmus D, Ponikowski P, et al. The predictive value of short-term changes in hemoglobin concentration in patients presenting with acute decompensated heart failure. J Am Coll Cardiol. 2013; 61(19): 1973–1981.
- Testani JM, Brisco MA, Chen J, et al. Timing of hemoconcentration during treatment of acute decompensated heart failure and subsequent survival: importance of sustained decongestion. J Am Coll Cardiol. 2013; 62(6): 516–524.
- Brandimarte F, Vaduganathan M, Mureddu GF, et al. Prognostic implications of renal dysfunction in patients hospitalized with heart failure: data from the last decade of clinical investigations. Heart Fail Rev. 2013; 18(2): 167–176.
- Bart BA, Goldsmith SR, Lee KL, et al. NHLBI Heart Failure Clinical Research Network. Diuretic strategies in patients with acute decompensated heart failure. N Engl J Med. 2011; 364(9): 797–805.
- Felker GM, Mentz RJ. Diuretics and ultrafiltration in acute decompensated heart failure. J Am Coll Cardiol. 2012; 59(24): 2145–2153.
- Valente MAE, Voors AA, Damman K, et al. Diuretic response in acute heart failure: clinical characteristics and prognostic significance. Eur Heart J. 2014; 35(19): 1284–1293.
- Testani JM, Brisco MA, Turner JM, et al. Loop diuretic efficiency: a metric of diuretic responsiveness with prognostic importance in acute decompensated heart failure. Circ Heart Fail. 2014; 7(2): 261–270.
- Porapakkham P, Porapakkham P, Zimmet H, et al. B-type natriuretic peptide-guided heart failure therapy: a meta-analysis. Arch Intern Med. 2010; 170(6): 507–514.
- Berger R, Moertl D, Peter S, et al. N-terminal pro-B-type natriuretic peptide-guided, intensive patient management in addition to multidisciplinary care in chronic heart failure a 3-arm, prospective, randomized pilot study. J Am Coll Cardiol. 2010; 55(7): 645–653.
- Januzzi JL, Rehman SU, Mohammed AA, et al. Use of amino-terminal pro-B-type natriuretic peptide to guide outpatient therapy of patients with chronic left ventricular systolic dysfunction. J Am Coll Cardiol. 2011; 58(18): 1881–1889.
- Savarese G, Musella F, D'Amore C, et al. Changes of natriuretic peptides predict hospital admissions in patients with chronic heart failure: a meta-analysis. JACC Heart Fail. 2014; 2(2): 148–158.
